Company

ProfoundBio US Co.

ProfoundBio develops antibody-based medicines, including antibody-drug conjugates, for cancer treatment.

About

Founded in 2018 and based in Woodinville, US, ProfoundBio develops antibody-based oncology medicines, including antibody-drug conjugates. Its pipeline includes PRO1184, targeting folate receptor alpha, and PRO1160, targeting CD70 in hematologic and solid tumors. Genmab A/S acquired the company in May 2024 for USD 1.8 billion.

4Funding rounds

12Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in